Učitavanje...
PRDM1 is required for Mantle Cell Lymphoma response to Bortezomib
Mantle cell lymphoma (MCL) is an aggressive form of B cell lymphoma with a poor disease- free survival rate. The proteasome inhibitor, Bortezomib, is approved for treatment of relapsed and refractory MCL and has efficacy in about 30% of patients. However, the precise mechanism of action of Bortezomi...
Spremljeno u:
| Glavni autori: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2010
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2891394/ https://ncbi.nlm.nih.gov/pubmed/20530581 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-10-0131 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|